Profile data is unavailable for this security.
About the company
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
- Revenue in CHF (TTM)503.23m
- Net income in CHF114.68m
- Incorporated1971
- Employees1.64k
- LocationBachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
- Phone+41 619352333
- Fax+41 619352324
- Websitehttp://www.bachem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitrolife AB | 191.20m | 28.37m | 3.11bn | 1.17k | 96.94 | 2.15 | 68.28 | 16.29 | 2.55 | 2.55 | 16.93 | 114.69 | 0.1864 | 3.03 | 6.30 | 4,809,944.00 | 2.78 | 8.88 | 2.94 | 9.55 | 59.31 | 63.53 | 14.93 | 24.08 | 1.17 | 23.18 | 0.1365 | 23.22 | 34.94 | 14.45 | 18.87 | 12.36 | 35.34 | 9.00 |
| Krka d.d. Novo Mesto | 1.60bn | 313.29m | 3.12bn | 11.63k | 9.45 | 1.49 | 7.41 | 1.94 | 10.05 | 10.05 | 51.46 | 63.71 | 0.6453 | 1.51 | 3.56 | 139,212.30 | 12.58 | 11.07 | 15.06 | 13.24 | 56.98 | 57.68 | 19.50 | 16.24 | 2.16 | -- | 0.0059 | 56.33 | 2.01 | 5.92 | 6.26 | 23.31 | -9.89 | 15.41 |
| Virbac SA | 1.06bn | 113.24m | 3.13bn | 5.10k | 27.62 | 4.31 | 19.70 | 2.94 | 13.40 | 13.40 | 125.95 | 85.82 | 0.9208 | 2.32 | 10.18 | 207,805.70 | 10.00 | 5.26 | 14.49 | 7.54 | 47.50 | 47.46 | 10.86 | 7.10 | 0.9557 | 20.29 | 0.1153 | 5.31 | 13.89 | 4.06 | -16.82 | 26.71 | 3.33 | -- |
| Abcam Plc | 366.06m | 4.53m | 3.19bn | 1.75k | 705.40 | 4.19 | 60.09 | 8.73 | 0.017 | 0.017 | 1.38 | 2.87 | 0.3487 | 1.79 | 6.68 | 180,228.60 | 0.4312 | -- | 0.4979 | -- | 71.21 | -- | 1.24 | -- | 0.8189 | 56.20 | 0.2593 | -- | -- | -- | -- | -- | -- | -- |
| Laboratorios Farmaceuticos ROVI SA | 724.19m | 182.41m | 3.23bn | 1.75k | 17.53 | 7.52 | 16.12 | 4.47 | 3.29 | 3.29 | 13.06 | 7.67 | 1.08 | 1.22 | 5.53 | 413,312.40 | 27.28 | 12.56 | 37.62 | 16.27 | 60.76 | 58.31 | 25.19 | 14.22 | 1.10 | 324.76 | 0.1452 | 33.04 | 54.46 | 19.59 | 150.71 | 42.46 | 17.76 | 39.18 |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.65bn | 374.77m | 3.24bn | 12.17k | 8.62 | 1.37 | 6.55 | 1.97 | 805.00 | 805.00 | 3,535.43 | 5,083.67 | 0.6145 | 2.25 | 4.11 | -- | 14.21 | 7.87 | 15.95 | 8.95 | 55.80 | 55.98 | 23.13 | 13.18 | 2.42 | -- | 0.0174 | 37.82 | 11.26 | 10.10 | 33.38 | 16.10 | 31.49 | 16.23 |
| ALK-Abello A/S | 544.73m | 34.30m | 3.47bn | 2.57k | 109.44 | 7.66 | 50.33 | 6.36 | 1.16 | 1.16 | 18.45 | 16.60 | 0.6892 | 1.34 | 5.89 | 1,596,374.00 | 4.34 | -0.5115 | 5.47 | -0.6163 | 61.85 | 58.11 | 6.30 | -0.8118 | 0.9756 | 20.06 | 0.146 | -- | 12.17 | 5.44 | 776.00 | -4.10 | 3.17 | -- |
| Galapagos NV | 558.84m | -125.99m | 3.56bn | 1.31k | -- | 1.34 | -- | 6.37 | -1.59 | -1.59 | 9.93 | 40.31 | 0.1042 | -- | 5.13 | 426,634.10 | -2.35 | -2.45 | -2.64 | -2.75 | 71.80 | -- | -22.54 | -17.82 | 8.41 | -- | 0.0095 | -- | 1.57 | 28.86 | 59.67 | -- | 64.60 | -- |
| Hikma Pharmaceuticals Plc | 2.45bn | 404.02m | 4.17bn | 8.70k | 10.84 | 1.85 | 7.40 | 1.70 | 1.50 | 1.50 | 9.06 | 8.76 | 0.6002 | 1.72 | 3.70 | 242,557.00 | 9.87 | 3.80 | 13.05 | 5.21 | 50.96 | 50.90 | 16.45 | 6.61 | 1.38 | 10.35 | 0.2554 | 71.43 | 9.06 | 5.54 | -2.32 | 22.12 | 3.80 | 11.07 |
| Evotec SE | 650.05m | 89.63m | 4.22bn | 4.35k | 40.82 | 3.22 | -- | 6.50 | 0.5845 | 0.5845 | 3.83 | 7.41 | 0.345 | 24.03 | 5.22 | 154,745.40 | 4.76 | 6.81 | 5.62 | 8.42 | 23.58 | 27.40 | 13.79 | 16.62 | 3.05 | -- | 0.2836 | 0.00 | 23.38 | 30.31 | 3,332.78 | 50.91 | 63.60 | -- |
| Dechra Pharmaceuticals plc | 743.49m | 84.61m | 4.40bn | 1.95k | 52.23 | 5.93 | 23.32 | 5.92 | 0.6697 | 0.6697 | 5.89 | 5.90 | 0.5375 | 1.90 | 7.42 | 329,357.30 | 6.12 | 3.37 | 6.87 | 3.79 | 56.88 | 56.47 | 11.38 | 6.85 | 1.75 | 13.57 | 0.3314 | 97.78 | 18.04 | 19.69 | 63.72 | 34.37 | 78.18 | 17.02 |
| H. Lundbeck A/S | 2.21bn | 149.16m | 4.82bn | 5.35k | 6.47 | 0.3889 | 12.97 | 2.19 | 5.58 | 5.58 | 82.56 | 92.86 | 0.4716 | 1.16 | 4.22 | 3,066,193.00 | 3.19 | 8.13 | 4.13 | 11.54 | 78.37 | 78.05 | 6.76 | 13.60 | 0.7058 | 2.90 | 0.2597 | 48.48 | -7.77 | 0.8366 | -16.64 | 1.71 | 12.34 | -3.98 |
| BACHEM HOLDING AG | 503.23m | 114.68m | 4.97bn | 1.64k | 41.70 | 2.75 | 34.76 | 9.88 | 1.62 | 1.62 | 7.10 | 24.52 | 0.5009 | 1.30 | 5.50 | 307,037.20 | 11.41 | 9.82 | 13.20 | 12.30 | 33.13 | 31.43 | 22.79 | 19.02 | 4.17 | -- | 0.0183 | 63.76 | 25.18 | 16.30 | 46.91 | 22.72 | 18.43 | 6.96 |
| Orion Oyj | 1.04bn | 191.53m | 5.99bn | 3.38k | 31.19 | 9.32 | 25.62 | 5.74 | 1.36 | 1.36 | 7.41 | 4.55 | 0.8654 | 1.66 | 6.05 | 310,849.50 | 15.90 | 18.94 | 24.31 | 23.82 | 57.92 | 59.52 | 18.37 | 19.89 | 1.08 | 2,397.00 | 0.1709 | 101.61 | -3.44 | -0.613 | -11.87 | -4.89 | 12.25 | -0.6537 |
| Swedish Orphan Biovitrum AB (publ) | 1.56bn | 235.06m | 6.35bn | 1.57k | 26.13 | 2.76 | 13.77 | 4.06 | 8.49 | 8.49 | 56.55 | 80.49 | 0.3462 | 1.33 | 4.74 | 10,771,650.00 | 5.20 | 8.45 | 6.50 | 10.61 | 74.55 | 76.41 | 15.03 | 21.08 | 0.6623 | 8.18 | 0.2915 | 0.00 | 1.76 | 24.44 | -17.44 | 27.31 | 17.53 | -- |
| DiaSorin SpA | -100.07bn | -100.07bn | 7.07bn | 3.36k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.63 | -- | 19.02 | -- | 67.86 | -- | 24.99 | -- | -- | -- | 25.24 | 40.43 | 16.80 | 25.46 | 22.58 | 25.68 | 5.59 |
Data as of Jul 01 2022. Currency figures normalised to Bachem Holding AG's reporting currency: Swiss Franc CHF
11.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Dec 2021 | 2.13m | 2.89% |
| BlackRock Investment Management (UK) Ltd.as of 31 May 2022 | 1.13m | 1.54% |
| VV Verm�gensverwaltung AGas of 29 Apr 2022 | 977.50k | 1.33% |
| The Vanguard Group, Inc.as of 02 Jun 2022 | 854.97k | 1.16% |
| UBS Asset Management Switzerland AGas of 31 May 2022 | 736.72k | 1.00% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 729.50k | 0.99% |
| Abrdn Investment Management Ltd.as of 31 Dec 2021 | 604.26k | 0.82% |
| Vontobel Asset Management AGas of 31 May 2022 | 603.29k | 0.82% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 May 2022 | 533.19k | 0.72% |
| BlackRock Fund Advisorsas of 02 Jun 2022 | 525.40k | 0.71% |
More ▼
Data from 31 Dec 2021 - 29 Apr 2022Source: FactSet Research Systems Inc.
